237 related articles for article (PubMed ID: 8788036)
1. Topoisomerase II inhibitors affect entry into mitosis and chromosome condensation in BHK cells.
Anderson H; Roberge M
Cell Growth Differ; 1996 Jan; 7(1):83-90. PubMed ID: 8788036
[TBL] [Abstract][Full Text] [Related]
2. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
[TBL] [Abstract][Full Text] [Related]
3. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
Morgan SE; Cadena RS; Raimondi SC; Beck WT
Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
[TBL] [Abstract][Full Text] [Related]
4. Teniposide-resistant CEM cells, which express mutant DNA topoisomerase II alpha, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme.
Chen M; Beck WT
Cancer Res; 1993 Dec; 53(24):5946-53. PubMed ID: 8261408
[TBL] [Abstract][Full Text] [Related]
5. Differences in inhibition of chromosome separation and G2 arrest by DNA topoisomerase II inhibitors merbarone and VM-26.
Chen M; Beck WT
Cancer Res; 1995 Apr; 55(7):1509-16. PubMed ID: 7882360
[TBL] [Abstract][Full Text] [Related]
6. A topoisomerase II-dependent G2 cycle checkpoint in mammalian cells/.
Downes CS; Clarke DJ; Mullinger AM; Giménez-Abián JF; Creighton AM; Johnson RT
Nature; 1994 Dec; 372(6505):467-70. PubMed ID: 7984241
[TBL] [Abstract][Full Text] [Related]
7. Differential cell cycle-specificity for chromosomal damage induced by merbarone and etoposide in V79 cells.
Wang L; Roy SK; Eastmond DA
Mutat Res; 2007 Mar; 616(1-2):70-82. PubMed ID: 17174356
[TBL] [Abstract][Full Text] [Related]
8. Fostriecin-mediated G2-M-phase growth arrest correlates with abnormal centrosome replication, the formation of aberrant mitotic spindles, and the inhibition of serine/threonine protein phosphatase activity.
Cheng A; Balczon R; Zuo Z; Koons JS; Walsh AH; Honkanen RE
Cancer Res; 1998 Aug; 58(16):3611-9. PubMed ID: 9721869
[TBL] [Abstract][Full Text] [Related]
9. Conjugation of human topoisomerase 2 alpha with small ubiquitin-like modifiers 2/3 in response to topoisomerase inhibitors: cell cycle stage and chromosome domain specificity.
Agostinho M; Santos V; Ferreira F; Costa R; Cardoso J; Pinheiro I; Rino J; Jaffray E; Hay RT; Ferreira J
Cancer Res; 2008 Apr; 68(7):2409-18. PubMed ID: 18381449
[TBL] [Abstract][Full Text] [Related]
10. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
11. G2 arrest in response to topoisomerase II inhibitors: the role of p53.
Clifford B; Beljin M; Stark GR; Taylor WR
Cancer Res; 2003 Jul; 63(14):4074-81. PubMed ID: 12874009
[TBL] [Abstract][Full Text] [Related]
12. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
13. [Flow cytometric analysis of ICRF-193 influence on cell passage through mitosis].
Shatrova A; Aksenov ND; Zenin VV
Tsitologiia; 2002; 44(11):1068-78. PubMed ID: 12561727
[TBL] [Abstract][Full Text] [Related]
14. Catalytic inhibitors of topoisomerase II are DNA-damaging agents: induction of chromosomal damage by merbarone and ICRF-187.
Wang L; Eastmond DA
Environ Mol Mutagen; 2002; 39(4):348-56. PubMed ID: 12112387
[TBL] [Abstract][Full Text] [Related]
15. Interference with topoisomerase IIalpha potentiates melphalan cytotoxicity.
Hirota H; Gosky D; Berger NA; Chatterjee S
Int J Oncol; 2002 Feb; 20(2):311-8. PubMed ID: 11788894
[TBL] [Abstract][Full Text] [Related]
16. Application of fluorescence in situ hybridisation to study the relationship between cytotoxicity, chromosome aberrations, and changes in chromosome number after treatment with the topoisomerase II inhibitor amsacrine.
Ferguson LR; Whiteside G; Holdaway KM; Baguley BC
Environ Mol Mutagen; 1996; 27(4):255-62. PubMed ID: 8665870
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors.
Ishida R; Miki T; Narita T; Yui R; Sato M; Utsumi KR; Tanabe K; Andoh T
Cancer Res; 1991 Sep; 51(18):4909-16. PubMed ID: 1654205
[TBL] [Abstract][Full Text] [Related]
18. Antitumor drug fostriecin inhibits the mitotic entry checkpoint and protein phosphatases 1 and 2A.
Roberge M; Tudan C; Hung SM; Harder KW; Jirik FR; Anderson H
Cancer Res; 1994 Dec; 54(23):6115-21. PubMed ID: 7954457
[TBL] [Abstract][Full Text] [Related]
19. Cell cycle progression and chromosome segregation in mammalian cells cultured in the presence of the topoisomerase II inhibitors ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane; ADR-529] and ICRF-159 (Razoxane).
Gorbsky GJ
Cancer Res; 1994 Feb; 54(4):1042-8. PubMed ID: 8313360
[TBL] [Abstract][Full Text] [Related]
20. Ku antigen is required to relieve G2 arrest caused by inhibition of DNA topoisomerase II activity by the bisdioxopiperazine ICRF-193.
Muñoz P; Baus F; Piette J
Oncogene; 2001 Apr; 20(16):1990-9. PubMed ID: 11360183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
